Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 15/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11918890 | 0.84 | SMN1; SMN2 (0.38) | SMN1; SMN2PBRM1L3MBTL1BRD4POLB | |
| SCHEMBL18323676 | 0.82 | POLB (0.53) | BRD4ALDH1A1RECQLPOLB | |
| SCHEMBL15907072 | 0.81 | MEN1 (0.51) | SMN1; SMN2ALDH1A1RECQLPOLB | |
| SCHEMBL18323638 | 0.78 | KDM4E (0.50) | BRD4KDM4EDPP4 | |
| SCHEMBL18323581 | 0.73 | KDM4E (0.34) | BRD4ALDH1A1KDM4E | |
| SCHEMBL18323633 | 0.72 | BRD4 (0.38) | SMN1; SMN2BRD4ALDH1A1POLBKDM4E | |
| SCHEMBL18323590 | 0.71 | KDM4E (0.39) | SMN1; SMN2L3MBTL1ALDH1A1POLBKDM4E | |
| SCHEMBL11914813 | 0.66 | MPO (0.35) | ALDH1A1POLBKDM4E | |
| SCHEMBL11377976 | 0.65 | SMN1; SMN2 (0.47) | SMN1; SMN2PBRM1L3MBTL1BRD4POLB | |
| SCHEMBL18323663 | 0.64 | SMN1; SMN2 (0.42) | SMN1; SMN2PBRM1L3MBTL1BRD4POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9522910-B2 | Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon | Obshchestvo s ogranichennoy otvetstvennostyou “Fusion Pharma” (RU) | 2016-12-20 | — | — | US | disclosed |